Antigenics Inc. (New York) Provides Update on Filing for Approval of Oncophage(R) in Russia for the Treatment of Intermediate-Risk Kidney Cancer

NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that it has completed the submission of an application for marketing authorization with the Russian Ministry of Public Health for the use of Oncophage® (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence.

Back to news